Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome.

Ferritin Gut microbiome Iron status Metagenomics Non-alcoholic fatty liver disease Obesity Shotgun sequencing Systems medicine

Journal

Microbiome
ISSN: 2049-2618
Titre abrégé: Microbiome
Pays: England
ID NLM: 101615147

Informations de publication

Date de publication:
07 05 2021
Historique:
received: 13 10 2020
accepted: 18 03 2021
entrez: 8 5 2021
pubmed: 9 5 2021
medline: 20 5 2021
Statut: epublish

Résumé

The gut microbiome and iron status are known to play a role in the pathophysiology of non-alcoholic fatty liver disease (NAFLD), although their complex interaction remains unclear. Here, we applied an integrative systems medicine approach (faecal metagenomics, plasma and urine metabolomics, hepatic transcriptomics) in 2 well-characterised human cohorts of subjects with obesity (discovery n = 49 and validation n = 628) and an independent cohort formed by both individuals with and without obesity (n = 130), combined with in vitro and animal models. Serum ferritin levels, as a markers of liver iron stores, were positively associated with liver fat accumulation in parallel with lower gut microbial gene richness, composition and functionality. Specifically, ferritin had strong negative associations with the Pasteurellaceae, Leuconostocaceae and Micrococcaea families. It also had consistent negative associations with several Veillonella, Bifidobacterium and Lactobacillus species, but positive associations with Bacteroides and Prevotella spp. Notably, the ferritin-associated bacterial families had a strong correlation with iron-related liver genes. In addition, several bacterial functions related to iron metabolism (transport, chelation, heme and siderophore biosynthesis) and NAFLD (fatty acid and glutathione biosynthesis) were also associated with the host serum ferritin levels. This iron-related microbiome signature was linked to a transcriptomic and metabolomic signature associated to the degree of liver fat accumulation through hepatic glucose metabolism. In particular, we found a consistent association among serum ferritin, Pasteurellaceae and Micrococcacea families, bacterial functions involved in histidine transport, the host circulating histidine levels and the liver expression of GYS2 and SEC24B. Serum ferritin was also related to bacterial glycine transporters, the host glycine serum levels and the liver expression of glycine transporters. The transcriptomic findings were replicated in human primary hepatocytes, where iron supplementation also led to triglycerides accumulation and induced the expression of lipid and iron metabolism genes in synergy with palmitic acid. We further explored the direct impact of the microbiome on iron metabolism and liver fact accumulation through transplantation of faecal microbiota into recipient's mice. In line with the results in humans, transplantation from 'high ferritin donors' resulted in alterations in several genes related to iron metabolism and fatty acid accumulation in recipient's mice. Altogether, a significant interplay among the gut microbiome, iron status and liver fat accumulation is revealed, with potential significance for target therapies. Video abstract.

Sections du résumé

BACKGROUND
The gut microbiome and iron status are known to play a role in the pathophysiology of non-alcoholic fatty liver disease (NAFLD), although their complex interaction remains unclear.
RESULTS
Here, we applied an integrative systems medicine approach (faecal metagenomics, plasma and urine metabolomics, hepatic transcriptomics) in 2 well-characterised human cohorts of subjects with obesity (discovery n = 49 and validation n = 628) and an independent cohort formed by both individuals with and without obesity (n = 130), combined with in vitro and animal models. Serum ferritin levels, as a markers of liver iron stores, were positively associated with liver fat accumulation in parallel with lower gut microbial gene richness, composition and functionality. Specifically, ferritin had strong negative associations with the Pasteurellaceae, Leuconostocaceae and Micrococcaea families. It also had consistent negative associations with several Veillonella, Bifidobacterium and Lactobacillus species, but positive associations with Bacteroides and Prevotella spp. Notably, the ferritin-associated bacterial families had a strong correlation with iron-related liver genes. In addition, several bacterial functions related to iron metabolism (transport, chelation, heme and siderophore biosynthesis) and NAFLD (fatty acid and glutathione biosynthesis) were also associated with the host serum ferritin levels. This iron-related microbiome signature was linked to a transcriptomic and metabolomic signature associated to the degree of liver fat accumulation through hepatic glucose metabolism. In particular, we found a consistent association among serum ferritin, Pasteurellaceae and Micrococcacea families, bacterial functions involved in histidine transport, the host circulating histidine levels and the liver expression of GYS2 and SEC24B. Serum ferritin was also related to bacterial glycine transporters, the host glycine serum levels and the liver expression of glycine transporters. The transcriptomic findings were replicated in human primary hepatocytes, where iron supplementation also led to triglycerides accumulation and induced the expression of lipid and iron metabolism genes in synergy with palmitic acid. We further explored the direct impact of the microbiome on iron metabolism and liver fact accumulation through transplantation of faecal microbiota into recipient's mice. In line with the results in humans, transplantation from 'high ferritin donors' resulted in alterations in several genes related to iron metabolism and fatty acid accumulation in recipient's mice.
CONCLUSIONS
Altogether, a significant interplay among the gut microbiome, iron status and liver fat accumulation is revealed, with potential significance for target therapies. Video abstract.

Identifiants

pubmed: 33962692
doi: 10.1186/s40168-021-01052-7
pii: 10.1186/s40168-021-01052-7
pmc: PMC8106161
doi:

Substances chimiques

Iron E1UOL152H7

Types de publication

Journal Article Research Support, Non-U.S. Gov't Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Pagination

104

Subventions

Organisme : Medical Research Council
ID : MR/L01632X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M501797/1
Pays : United Kingdom

Références

Antioxid Redox Signal. 2013 Sep 20;19(9):1026-35
pubmed: 23249217
Annu Rev Immunol. 2011;29:415-45
pubmed: 21219177
Am J Physiol Gastrointest Liver Physiol. 2018 May 1;314(5):G597-G609
pubmed: 29420067
Glia. 2015 Oct;63(10):1738-52
pubmed: 25903009
Diabetes. 2013 Jul;62(7):2266-77
pubmed: 23474485
Hepatology. 2021 Jan;73(1):126-143
pubmed: 32794259
Cell Metab. 2011 Dec 7;14(6):804-10
pubmed: 22152305
J Gastroenterol. 2020 Feb;55(2):142-158
pubmed: 31845054
Cell Metab. 2017 May 2;25(5):1054-1062.e5
pubmed: 28467925
J Hepatol. 2009 Feb;50(2):249-51
pubmed: 19070915
Nat Med. 2018 Jul;24(7):1070-1080
pubmed: 29942096
Front Microbiol. 2017 Dec 12;8:2431
pubmed: 29312162
J Hepatol. 2018 Oct;69(4):927-947
pubmed: 29940269
Crit Rev Biochem Mol Biol. 2017 Jun;52(3):314-326
pubmed: 28276700
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Int J Biol Macromol. 2020 Feb 15;145:1208-1218
pubmed: 31726162
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Biol Chem. 2017 Jun 23;292(25):10455-10464
pubmed: 28483921
Clin Chem. 2018 Feb;64(2):374-385
pubmed: 29038157
Cell. 2017 Jan 26;168(3):344-361
pubmed: 28129536
J Trace Elem Med Biol. 2018 May;47:12-20
pubmed: 29544798
Biomedicines. 2020 Aug 03;8(8):
pubmed: 32756350
Nature. 2014 Jan 23;505(7484):559-63
pubmed: 24336217
Nucleic Acids Res. 2009 Jan;37(Database issue):D623-8
pubmed: 18940869
Int J Obes (Lond). 2017 Apr;41(4):620-630
pubmed: 28119530
Gastroenterology. 2014 Apr;146(4):1060-9
pubmed: 24361124
Mol Syst Biol. 2017 Mar 2;13(3):916
pubmed: 28254760
BMC Bioinformatics. 2018 Oct 11;19(1):371
pubmed: 30309317
Mol Metab. 2016 Oct 31;6(1):38-47
pubmed: 28123936
Sci Rep. 2015 Sep 11;5:13980
pubmed: 26358367
FEMS Microbiol Rev. 2003 Jun;27(2-3):215-37
pubmed: 12829269
Hepatology. 2017 Jan;65(1):350-362
pubmed: 27358174
Nature. 2011 Jun 15;474(7351):327-36
pubmed: 21677749
Clin Nutr. 2021 Jan;40(1):207-216
pubmed: 32536582
Sci Transl Med. 2017 May 17;9(390):
pubmed: 28515336
AJR Am J Roentgenol. 2007 Dec;189(6):W320-3
pubmed: 18029843
Nature. 2013 Aug 29;500(7464):585-8
pubmed: 23985875
Hepatology. 2012 Jan;55(1):77-85
pubmed: 21953442
Hepatology. 2013 Feb;57(2):601-9
pubmed: 23055155
Hepatology. 2016 Mar;63(3):764-75
pubmed: 26600078
Hepatol Commun. 2017 Apr;1(2):122-139
pubmed: 28626835

Auteurs

Jordi Mayneris-Perxachs (J)

Department of Endocrinology, Diabetes and Nutrition, Hospital of Girona "Dr Josep Trueta", Girona, Spain.
Departament de Ciències Mèdiques, University of Girona, Girona and Biomedical Research Institute of Girona (IdibGi), Girona, Spain.
CIBERobn Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Girona, Spain.

Marina Cardellini (M)

Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.

Lesley Hoyles (L)

Section of Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Exhibition Road, London, SW7 2AZ, UK.
Department of Bioscience, School of Science and Technology, Nottingham Trent University, Nottingham, NG11 8NS, UK.

Jèssica Latorre (J)

Department of Endocrinology, Diabetes and Nutrition, Hospital of Girona "Dr Josep Trueta", Girona, Spain.
Departament de Ciències Mèdiques, University of Girona, Girona and Biomedical Research Institute of Girona (IdibGi), Girona, Spain.
CIBERobn Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Girona, Spain.

Francesca Davato (F)

Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.

José Maria Moreno-Navarrete (JM)

Department of Endocrinology, Diabetes and Nutrition, Hospital of Girona "Dr Josep Trueta", Girona, Spain.
Departament de Ciències Mèdiques, University of Girona, Girona and Biomedical Research Institute of Girona (IdibGi), Girona, Spain.
CIBERobn Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Girona, Spain.

María Arnoriaga-Rodríguez (M)

Department of Endocrinology, Diabetes and Nutrition, Hospital of Girona "Dr Josep Trueta", Girona, Spain.
Departament de Ciències Mèdiques, University of Girona, Girona and Biomedical Research Institute of Girona (IdibGi), Girona, Spain.
CIBERobn Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Girona, Spain.

Matteo Serino (M)

Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.
Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Team 2: 'Intestinal Risk Factors, Diabetes, Dyslipidemia, and Heart Failure', 31432, Toulouse Cedex 4, France.

James Abbott (J)

Section of Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Exhibition Road, London, SW7 2AZ, UK.

Richard H Barton (RH)

Section of Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Exhibition Road, London, SW7 2AZ, UK.

Josep Puig (J)

Department of Endocrinology, Diabetes and Nutrition, Hospital of Girona "Dr Josep Trueta", Girona, Spain.
Departament de Ciències Mèdiques, University of Girona, Girona and Biomedical Research Institute of Girona (IdibGi), Girona, Spain.
CIBERobn Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Girona, Spain.

Xavier Fernández-Real (X)

EPFL, Lausanne, Switzerland.

Wifredo Ricart (W)

Department of Endocrinology, Diabetes and Nutrition, Hospital of Girona "Dr Josep Trueta", Girona, Spain.
Departament de Ciències Mèdiques, University of Girona, Girona and Biomedical Research Institute of Girona (IdibGi), Girona, Spain.
CIBERobn Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Girona, Spain.

Christopher Tomlinson (C)

Section of Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Exhibition Road, London, SW7 2AZ, UK.

Mark Woodbridge (M)

Section of Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Exhibition Road, London, SW7 2AZ, UK.

Paolo Gentileschi (P)

Department of Surgery, University of Rome Tor Vergata, Rome, Italy.

Sarah A Butcher (SA)

Section of Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Exhibition Road, London, SW7 2AZ, UK.

Elaine Holmes (E)

Section of Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Exhibition Road, London, SW7 2AZ, UK.

Jeremy K Nicholson (JK)

Section of Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Exhibition Road, London, SW7 2AZ, UK.

Vicente Pérez-Brocal (V)

Unidad Mixta de Investigación en Genómica y Salud, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) and Instituto de Biología Integrativa de Sistemas, Universitat de València and Consejo Superior de Investigaciones Científicas (CSIC), València, Spain.
CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Andrés Moya (A)

Unidad Mixta de Investigación en Genómica y Salud, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) and Instituto de Biología Integrativa de Sistemas, Universitat de València and Consejo Superior de Investigaciones Científicas (CSIC), València, Spain.
CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Donald Mc Clain (DM)

Department of Internal Medicine, Wake Forest School of Medicine, Winston Salem, NC, 27157, USA.
The W. G. Hefner Veterans Affairs Medical Center, Salisbury, NC, 28144, USA.

Rémy Burcelin (R)

Institut National de la Santé et de la Recherche Médicale (INSERM), Toulouse, France.
Université Paul Sabatier (UPS), Unité Mixte de Recherche (UMR) 1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Team 2: 'Intestinal Risk Factors, Diabetes, Dyslipidemia, and Heart Failure', 31432, Toulouse Cedex 4, France.

Marc-Emmanuel Dumas (ME)

Section of Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, Exhibition Road, London, SW7 2AZ, UK.
Section of Genomic and Environmental Medicine, National Heart & Lung Institute, Imperial College London, Dovehouse Street, London, SW3 6LY, UK.
European Genomic Institute for Diabetes, CNRS UMR 8199, INSERM UMR 1283, Institut Pasteur de Lille, Lille University Hospital, University of Lille, 59045, Lille, France.
McGill University and Genome Quebec Innovation Centre, 740 Doctor Penfield Avenue, Montréal, QC, H3A 0G1, Canada.

Massimo Federici (M)

Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.

José-Manuel Fernández-Real (JM)

Department of Endocrinology, Diabetes and Nutrition, Hospital of Girona "Dr Josep Trueta", Girona, Spain. jmfreal@idibgi.org.
Departament de Ciències Mèdiques, University of Girona, Girona and Biomedical Research Institute of Girona (IdibGi), Girona, Spain. jmfreal@idibgi.org.
CIBERobn Pathophysiology of Obesity and Nutrition, Instituto de Salud Carlos III, Girona, Spain. jmfreal@idibgi.org.

Articles similaires

Humans Meals Time Factors Female Adult
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Classifications MeSH